In short
Rugonersen, a novel drug developed by F. Hoffmann-La Roche Ltd, is currently being studied in clinical trials for the treatment of Angelman Syndrome (AS). This open-label, multicenter study aims to assess the safety, tolerability, and effectiveness of Rugonersen in patients with AS. The trial involves multiple phases, including a Multiple Ascending Dose part, a Long-Term Extension part, and an Optional Open-Label Extension part, to thoroughly evaluate the drug's potential benefits for individuals with this rare genetic disorder.
At a glance
- Drug Name
- Rugonersen (RO7248824)
- Condition Studied
- Angelman Syndrome (AS)
- Study Type
- Open-Label, Multicenter, Phase I
- Primary Objective
- Assess safety and tolerability of Rugonersen
- Secondary Objective
- Investigate pharmacokinetics of Rugonersen
- Study Design
- Multiple Ascending Dose, Long-Term Extension, Optional Open-Label Extension
- Age Groups
- 1-4 years and 5-12 years
- Dosage Range
- 15-240 mg (varies by study phase and cohort)
- Administration
- Solution for injection
- Sponsor
- F. Hoffmann-La Roche Ltd
What is RUGONERSEN?
RUGONERSEN, also known by its product code RO 724-8824/F02-01, is a new medication being developed to treat Angelman Syndrome (AS). It is currently undergoing clinical trials to assess its safety, effectiveness, and how it behaves in the body of patients with this condition.
RUGONERSEN is classified as a solution for injection, which means it is given through an injection rather than taken orally. It is being developed by F. Hoffmann-La Roche Ltd and has been granted orphan drug designation (EU/3/20/2379) by the European Medicines Agency. This designation is given to drugs that are being developed to treat rare diseases.
What is Angelman Syndrome?
Angelman Syndrome (AS) is a rare genetic disorder that affects the nervous system. It is characterized by developmental delays, intellectual disability, severe speech impairment, and problems with movement and balance. AS is caused by problems with a gene called UBE3A on chromosome 15.
People with AS typically have:
- Delayed development
- Intellectual disability
- Severe speech impairment
- Problems with movement and balance
- Seizures
- Sleep disorders
- Characteristic facial features
How RUGONERSEN Works
RUGONERSEN is classified as a nucleic acid medication. While the exact mechanism of action is not provided in the clinical trial information, nucleic acid drugs typically work by targeting specific genes or their products. In the case of Angelman Syndrome, RUGONERSEN likely aims to address the underlying genetic cause of the condition, which is related to the UBE3A gene.
Clinical Trial Details
The clinical trial for RUGONERSEN is designed to investigate its safety, tolerability, and how it behaves in the body (pharmacokinetics and pharmacodynamics) of patients with Angelman Syndrome. This is a Phase I study, which means it's an early stage in the drug development process.
The trial is structured in three parts:
- Multiple Ascending Dose (MAD) Part: This part involves gradually increasing the dose of RUGONERSEN to determine the safest and most effective dose range.
- Long-Term Extension (LTE) Part: Participants who complete the MAD part may continue into this phase to assess the long-term effects of the medication.
- Optional Open-Label Extension (OOE) Part: This part allows participants to continue receiving the medication after the main study ends.
Eligibility Criteria
To participate in the RUGONERSEN clinical trial, patients must meet certain criteria. Some key inclusion criteria are:
- Have a clinical diagnosis of Angelman Syndrome confirmed by genetic testing
- Have a stable medical status for at least 4 weeks before screening
- Have adequate supportive care
- Be able to tolerate blood draws
Some reasons why a patient might not be eligible (exclusion criteria) include:
- Having significant health issues unrelated to Angelman Syndrome
- Known history of HIV, hepatitis B, or hepatitis C
- Any condition that increases the risk of meningitis
- History of bleeding disorders or significant headaches after lumbar punctures
Safety and Monitoring
The main goal of this clinical trial is to assess the safety and tolerability of RUGONERSEN. Throughout the study, researchers will closely monitor:
- Frequency and severity of side effects
- Changes in laboratory test results (blood and cerebrospinal fluid)
- Changes in vital signs (temperature, blood pressure, heart rate, breathing rate)
- Electrocardiogram (ECG) results
Dosing Information
The dosing of RUGONERSEN varies depending on the part of the study and the age of the participant:
- In the Multiple Ascending Dose part, doses range from 15 to 240 mg for participants aged 5-12 years, and 6 to 240 mg for those aged 1-4 years.
- In the Long-Term Extension part, doses range from 60 to 240 mg, given every 16 or 24 weeks, depending on the participant's previous dosing group.
Potential Benefits and Risks
As RUGONERSEN is still in early-stage clinical trials, its full benefits and risks are not yet known. However, as with any medical treatment, there are potential benefits and risks to consider:
Potential benefits:
- Improved management of Angelman Syndrome symptoms
- Contribution to the advancement of AS treatment research
Potential risks:
- Unknown side effects
- Discomfort from medical procedures (e.g., injections, blood draws)
- The possibility that the treatment may not be effective
It's important to note that as this is an early-stage clinical trial, the primary focus is on safety and tolerability rather than effectiveness. More research will be needed to fully understand the potential benefits and risks of RUGONERSEN for patients with Angelman Syndrome.